Interest of daratumumab in refractory AL amyloidosis in a 96-year-old patient
Copyright © 2022 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved..
Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by deposition of amyloid fibrils of light chains produced by clonal CD38+plasma cells, resulting in organ dysfunction. Cardiac involvement has a major prognostic value. Antiplasma cell chemotherapy reduces the synthesis of immunoglobulin light chains (precursors of amyloid deposits). We describe a case of AL amyloidosis in a 95-year-old patient. Our patient responded poorly to treatment with rituximab, cyclophosphamide-bortezomib-dexamethasone, and rituximab-bendamustine. Finally, the anti-CD38 antibody daratumumab was associated with the best hematologic responsiveness without significant adverse effects. In conclusion, our case suggests that daratumumab is an effective and well-tolerated alternative to chemotherapy in the treatment af AL amyloidosis in very elderly patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
La Revue de medecine interne - 43(2022), 11 vom: 05. Nov., Seite 673-676 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Intérêt du daratumumab dans l’amylose AL réfractaire chez une patiente de 96ans |
|---|
| Beteiligte Personen: |
Vial, G [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.11.2022 Date Revised 08.11.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.revmed.2022.07.013 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344540480 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344540480 | ||
| 003 | DE-627 | ||
| 005 | 20231226023016.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.revmed.2022.07.013 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1148.xml |
| 035 | |a (DE-627)NLM344540480 | ||
| 035 | |a (NLM)35934598 | ||
| 035 | |a (PII)S0248-8663(22)00579-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Vial, G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Interest of daratumumab in refractory AL amyloidosis in a 96-year-old patient |
| 246 | 3 | 3 | |a Intérêt du daratumumab dans l’amylose AL réfractaire chez une patiente de 96ans |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.11.2022 | ||
| 500 | |a Date Revised 08.11.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by deposition of amyloid fibrils of light chains produced by clonal CD38+plasma cells, resulting in organ dysfunction. Cardiac involvement has a major prognostic value. Antiplasma cell chemotherapy reduces the synthesis of immunoglobulin light chains (precursors of amyloid deposits). We describe a case of AL amyloidosis in a 95-year-old patient. Our patient responded poorly to treatment with rituximab, cyclophosphamide-bortezomib-dexamethasone, and rituximab-bendamustine. Finally, the anti-CD38 antibody daratumumab was associated with the best hematologic responsiveness without significant adverse effects. In conclusion, our case suggests that daratumumab is an effective and well-tolerated alternative to chemotherapy in the treatment af AL amyloidosis in very elderly patients | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AL amyloidosis | |
| 650 | 4 | |a Amylose AL | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Daratumumab | |
| 650 | 4 | |a Elderly | |
| 650 | 4 | |a Maladie réfractaire | |
| 650 | 4 | |a Refractory disease | |
| 650 | 4 | |a Âgé | |
| 650 | 7 | |a daratumumab |2 NLM | |
| 650 | 7 | |a 4Z63YK6E0E |2 NLM | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Immunoglobulin Light Chains |2 NLM | |
| 650 | 7 | |a Cyclophosphamide |2 NLM | |
| 650 | 7 | |a 8N3DW7272P |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 700 | 1 | |a Lafargue, A |e verfasserin |4 aut | |
| 700 | 1 | |a Mercié, P |e verfasserin |4 aut | |
| 700 | 1 | |a Duffau, P |e verfasserin |4 aut | |
| 700 | 1 | |a Ribeiro, E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t La Revue de medecine interne |d 1983 |g 43(2022), 11 vom: 05. Nov., Seite 673-676 |w (DE-627)NLM012660108 |x 1768-3122 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2022 |g number:11 |g day:05 |g month:11 |g pages:673-676 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.revmed.2022.07.013 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2022 |e 11 |b 05 |c 11 |h 673-676 | ||